Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PHGDH | O43175 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8440512 | 0.97 | TDP1 (0.35) | CYP1A2TDP1HRH4PHGDHMGLL | |
| SCHEMBL10780186 | 0.94 | LMNA (0.38) | CYP1A2TDP1LMNA | |
| SCHEMBL4831157 | 0.90 | TDP1 (0.35) | CYP1A2TDP1LMNAPHGDHMGLL | |
| SCHEMBL15217805 | 0.86 | CYP1A2 (0.40) | CYP1A2TDP1PHGDHMGLL | |
| SCHEMBL16015284 | 0.82 | LMNA (0.39) | CYP1A2TDP1HRH4LMNAPHGDH | |
| SCHEMBL17771605 | 0.82 | LMNA (0.39) | CYP1A2TDP1HRH4LMNAPHGDH | |
| N-Methylpiperidine SCHEMBL11878290 | 0.82 | LMNA (0.39) | CYP1A2TDP1HRH4LMNAPHGDH | |
| SCHEMBL6238723 | 0.82 | LMNA (0.39) | CYP1A2TDP1HRH4LMNAPHGDH | |
| SCHEMBL13835190 | 0.82 | — | — | |
| SCHEMBL19878898 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102264732-A | Pi3k/mtor kinase inhibitors | — | 2011-11-30 | — | — | CN | claimed |
| US-20090318424-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| US-20090239846-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2009-09-24 | — | — | US | claimed |
| US-7541359-B2 | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-02 | — | — | US | claimed |
| EP-2032142-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-11 | — | — | EP | claimed |
| WO-2007147109-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | claimed |
| EP-1866311-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | claimed |
| US-20070004741-A1 | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | APODACA RICHARD | 2007-01-04 | — | — | US | claimed |
| US-20060235030-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | claimed |
| WO-2006104889-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | claimed |
| EP-0033255-B1 | OXIMES DERIVED FROM ERYTHROMYCIN A, THEIR PREPARATION, THEIR APPLICATION IN PHARMACEUTICALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1984-08-29 | — | — | EP | claimed |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-31 | — | — | US | disclosed |
| EP-2300013-B2 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-13 | — | — | EP | disclosed |
| CN-118530229-A | Arctigenin derivative and preparation method and application thereof | 深圳市翰林生物医药科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20230181693-A1 | METHODS OF TREATING INFLAMMATORY SKIN DISORDERS | NEPSONE EHF (IS) | 2023-06-15 | — | — | US | disclosed |
| WO-2006104889-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006104915-A2 | 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES AND THEIR USE AS PHARMACEUTICALS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
| CN-1774435-A | 5-membered heterocyclic derivative | DAIICHI SEIYAKU CO (JP) | 2006-05-17 | — | — | CN | disclosed |
| EP-1163239-A1 | MODIFIED AMINO-ACID AMIDES AS CGRP ANTAGONISTS | Boehringer Ingelheim Pharma KG (DE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055154-A1 | MODIFIED AMINO-ACID AMIDES AS CGRP ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239846-A1 | Novel Compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | CYP1A2 4808/4885TDP1 2552/4885HRH4 3226/4885 |
| US-20060235030-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | CYP1A2 4808/4885TDP1 2552/4885HRH4 3226/4885 |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA1 | CYP1A2 403/4885TDP1 2277/4885HRH4 218/4885 |
| US-20070004741-A1 | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | FAAH, FAAH2, CNR2 | CYP1A2 900/4885TDP1 3958/4885HRH4 11/4885 |
| US-20090318424-A1 | NOVEL COMPOUNDS | MAPKAPK2, MAPKAPK3, CDC42BPB | CYP1A2 4808/4885TDP1 2552/4885HRH4 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.